Skip to content

FDA Greenlights Merck's Daily Cholesterol Tablet

The once-daily pill offers an alternative to injectable PCSK9 inhibitors currently dominating the cholesterol treatment market.

Pic via X

Merck said the U.S. Food and Drug Administration has approved Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor approved to treat high LDL, or "bad," cholesterol, reported by Reuters.

According to the report, the once-daily pill offers an alternative to injectable PCSK9 inhibitors currently dominating the cholesterol treatment market.

💡
Lipfendra works by blocking the PCSK9 protein, which regulates cholesterol levels, while traditional statins reduce cholesterol production in the liver through a different mechanism.

The FDA based its decision on two late-stage clinical trials showing the drug significantly lowered LDL cholesterol in patients, including those with familial hypercholesterolemia and individuals already taking statins.

Reuters reported that the approval supports Merck's strategy to diversify beyond its blockbuster cancer drug Keytruda, which is expected to face biosimilar competition after key patent protections begin expiring in 2028.

Analysts estimate Lipfendra could eventually generate tens of billions of dollars in peak annual sales.

Related Tweet:

Also Read:

Lilly Announces $2.8 Billion Psychedelics Acquisition
The deal values AtaiBeckley at $6.75 per share, a 26% premium over its previous closing price

Comments

Latest

Mayor Pete’s DEI Love Strands Millions

Mayor Pete’s DEI Love Strands Millions

It’s also significantly more, roughly $30 billion to $50 billion more, than the Trump administration says is needed to update the nation’s ramshackle air traffic control system.

Members Public
We Want Our Money Back

We Want Our Money Back

Another recent survey asked 2,188 undergraduates at five Chicago-area universities about whether they felt free to express pro-American views on campus.

Members Public